Hepatitis C virus non-structural proteins (NS3, NS4A, NS4B, NS5A, NS5B) (HCV NS3-5B)

The Hepatitis C virus (HCV) non-structural proteins NS3, NS4A, NS4B, NS5A, and NS5B are essential components of the viral replication machinery and primary targets for direct-acting antiviral (DAA) therapy [PubMed 25545014]. NS3 functions as both a serine protease (with its cofactor NS4A) to cleave the viral polyprotein and a helicase to unwind RNA during replication [UniProt P26664]. NS4B is responsible for inducing the membranous web, a specialized organelle where viral replication occurs, while NS5A is a multifunctional phosphoprotein critical for both RNA replication and viral assembly [PubMed 20812927]. NS5B serves as the RNA-dependent RNA polymerase (RdRp), the core enzyme responsible for synthesizing new viral RNA strands [PubMed 8623335]. Drugs targeting these proteins, such as protease inhibitors (NS3/4A), replication complex inhibitors (NS5A), and polymerase inhibitors (NS5B), have revolutionized the treatment of chronic hepatitis C, leading to high cure rates [NIH/NIDDK]. These DAAs work by directly interfering with the viral life cycle and are often used in combination to prevent the emergence of resistance [StatPearls]. However, challenges remain regarding drug resistance mutations and the risk of Hepatitis B virus (HBV) reactivation during treatment [FDA].

Other names

HCV non-structural polyproteinHCV NS3/4A proteaseHCV NS5A phosphoproteinHCV NS5B polymeraseHCV replication complex

Inhibition of NS3/4A serine protease to prevent polyprotein processing; inhibition of NS5A to disrupt viral replication and assembly; and inhibition of NS5B RNA-dependent RNA polymerase to terminate RNA synthesis.